| 1 | ≥ | 8,658 |
| 2 | ∼ | 260 |
| 3 | ≈ | 258 |
| 4 | ~ | 180 |
| 5 | ex-hn | 119 |
| 6 | ⩾ | 31 |
| 7 | ≧ | 24 |
| 8 | 10/hctz | 16 |
| 9 | azd2066 | 10 |
| 10 | bruker | 8 |
| 11 | tifton | 7 |
| 12 | pneumo | 6 |
| 13 | -timi | 5 |
| 14 | death= | 5 |
| 15 | modulo | 5 |
| 16 | 1980-week | 4 |
| 17 | 3-ni | 4 |
| 18 | 5/hctz | 4 |
| 19 | lipovenoes | 4 |
| 20 | novopen® | 4 |
| 21 | ≤day | 4 |
| 22 | 17/ | 3 |
| 23 | 3/cplx | 3 |
| 24 | ex-he | 3 |
| 25 | f3,64 | 3 |
| 26 | imatynib-biofarm | 3 |
| 27 | modradoc001 | 3 |
| 28 | t+nes | 3 |
| 29 | 0± | 2 |
| 30 | 1950-week | 2 |
| 31 | 21of | 2 |
| 32 | 3-alkynylindoles | 2 |
| 33 | 3± | 2 |
| 34 | 6/day | 2 |
| 35 | airpel | 2 |
| 36 | alendonate | 2 |
| 37 | coptis-evodia | 2 |
| 38 | elevation≥grade | 2 |
| 39 | greater-than-or-equal | 2 |
| 40 | interaction≥ | 2 |
| 41 | jimmy | 2 |
| 42 | kyse | 2 |
| 43 | n=continuous | 2 |
| 44 | oxanthrone | 2 |
| 45 | psmin | 2 |
| 46 | s.d.s | 2 |
| 47 | ≳ | 2 |
| 48 | +sertraline | 1 |
| 49 | -1.1+/- | 1 |
| 50 | -15±6.4 | 1 |
| 51 | -1h-1,2,4-triazole-3,5-diamine | 1 |
| 52 | -2.9± | 1 |
| 53 | -5-phenyl-1,3,4-oxadiazoles | 1 |
| 54 | -6.00d | 1 |
| 55 | -alpha-2b | 1 |
| 56 | -arylpyrroloindolines | 1 |
| 57 | -but-2-enenitrile | 1 |
| 58 | -n'-benzylidene-5-methyl-1,3-diphenyl-1h-pyrazole-4-carbohydrazide | 1 |
| 59 | -netupitant | 1 |
| 60 | -omeprazole | 1 |
| 61 | .adjunctive | 1 |
| 62 | .selenomethionine | 1 |
| 63 | .within | 1 |
| 64 | //www.projetodiretrizes.org.br/4_volume/06-diabetes-c.pdf | 1 |
| 65 | /ethanol | 1 |
| 66 | /mct | 1 |
| 67 | 0.20+/- | 1 |
| 68 | 0.20-1.25 | 1 |
| 69 | 0.20± | 1 |
| 70 | 0.21+/- | 1 |
| 71 | 0.21± | 1 |
| 72 | 1-ethynylazulene | 1 |
| 73 | 1.62/dbp | 1 |
| 74 | 1/grade | 1 |
| 75 | 11+/- | 1 |
| 76 | 11-minute | 1 |
| 77 | 13/of | 1 |
| 78 | 1500-17 | 1 |
| 79 | 1969-june | 1 |
| 80 | 2-aminoadamantane | 1 |
| 81 | 2.37+/-0.27 | 1 |
| 82 | 21± | 1 |
| 83 | 22.5± | 1 |
| 84 | 23.3±1.7 | 1 |
| 85 | 23.7°± | 1 |
| 86 | 25-train-of-four | 1 |
| 87 | 25th- | 1 |
| 88 | 27/ | 1 |
| 89 | 27and | 1 |
| 90 | 3-aryl-5,7-dimethoxyquinolin-4-ones | 1 |
| 91 | 3-methylene-2,3-dihydroindoles | 1 |
| 92 | 3/grade | 1 |
| 93 | 305/ | 1 |
| 94 | 333.0±3.6 | 1 |
| 95 | 349.3±3.6 | 1 |
| 96 | 37/ | 1 |
| 97 | 4.20mg | 1 |
| 98 | 41- | 1 |
| 99 | 42-minute | 1 |
| 100 | 43+/- | 1 |
| 101 | 43,4± | 1 |
| 102 | 44.7±2.1 | 1 |
| 103 | 51.2±0.1.9 | 1 |
| 104 | 54,8 | 1 |
| 105 | 55+/- | 1 |
| 106 | 57.41+/- | 1 |
| 107 | 58+/- | 1 |
| 108 | 5and | 1 |
| 109 | 63.3± | 1 |
| 110 | 7-sample | 1 |
| 111 | 7.0-ph | 1 |
| 112 | 7.9.± | 1 |
| 113 | 72.7+/- | 1 |
| 114 | 78+/- | 1 |
| 115 | 79+/- | 1 |
| 116 | 9-lu | 1 |
| 117 | 9beta,13alpha-dihydroxyisabellione | 1 |
| 118 | adimix | 1 |
| 119 | adolescentes | 1 |
| 120 | al-p. | 1 |
| 121 | alfa2a | 1 |
| 122 | alphacalcidiol | 1 |
| 123 | anthracene-1,4-diones | 1 |
| 124 | approixmately | 1 |
| 125 | arrivo | 1 |
| 126 | b=group | 1 |
| 127 | bp= | 1 |
| 128 | c4-spirocyclopropane | 1 |
| 129 | ca2+/creatinine | 1 |
| 130 | capilarema | 1 |
| 131 | ck- | 1 |
| 132 | clarinol™ | 1 |
| 133 | coltolux | 1 |
| 134 | cut-off-level | 1 |
| 135 | cyclohexa-1,3-diene | 1 |
| 136 | deltaeer-s/r | 1 |
| 137 | dermatoaphagoides | 1 |
| 138 | dimes® | 1 |
| 139 | eat- | 1 |
| 140 | eclia-elecsys | 1 |
| 141 | efforts-has | 1 |
| 142 | enoxaparin/clexane® | 1 |
| 143 | esomeprasol | 1 |
| 144 | esophagitis-weekly | 1 |
| 145 | ex-lhn | 1 |
| 146 | follows-after | 1 |
| 147 | fromnt | 1 |
| 148 | fyfanon | 1 |
| 149 | g-laser | 1 |
| 150 | g3- | 1 |
| 151 | gc/v | 1 |
| 152 | ghq-depression | 1 |
| 153 | gog104/swog | 1 |
| 154 | gpc3+hsp70 | 1 |
| 155 | ileoileoanastomoses | 1 |
| 156 | intake-serum | 1 |
| 157 | intratecttm | 1 |
| 158 | intravenous-lps | 1 |
| 159 | kt/vof | 1 |
| 160 | level≤ | 1 |
| 161 | levocetrizine | 1 |
| 162 | levorotated | 1 |
| 163 | limax® | 1 |
| 164 | lm75/ | 1 |
| 165 | losmapimod/placebo | 1 |
| 166 | m-chlorophenylisocyanate | 1 |
| 167 | macer | 1 |
| 168 | married/at | 1 |
| 169 | md=- | 1 |
| 170 | micomazole | 1 |
| 171 | midasolam | 1 |
| 172 | minusil | 1 |
| 173 | n-6/n- | 1 |
| 174 | napdh-oxidase | 1 |
| 175 | neurotrophin- | 1 |
| 176 | niacin/ | 1 |
| 177 | nn= | 1 |
| 178 | nnt= | 1 |
| 179 | novabac | 1 |
| 180 | npz | 1 |
| 181 | o-drive-od | 1 |
| 182 | octaethyloxochlorin | 1 |
| 183 | of≥ | 1 |
| 184 | ondatron | 1 |
| 185 | one-whole | 1 |
| 186 | overload-aim | 1 |
| 187 | paltry | 1 |
| 188 | parts-part | 1 |
| 189 | perylene-3,4,9,10-dianhydride | 1 |
| 190 | pg/mol | 1 |
| 191 | phenyl-methyl-siloxane | 1 |
| 192 | physio™ | 1 |
| 193 | placebo→golimumab | 1 |
| 194 | pneumonitis-weekly | 1 |
| 195 | q-yag | 1 |
| 196 | quartile-range | 1 |
| 197 | r=0.200 | 1 |
| 198 | reductions-approximately | 1 |
| 199 | repeat-derived | 1 |
| 200 | resvida™ | 1 |
| 201 | rlxu= | 1 |
| 202 | sarsaponin | 1 |
| 203 | sensitivity= | 1 |
| 204 | seventh-eighth | 1 |
| 205 | sfc/placebo | 1 |
| 206 | sponsor-mandated | 1 |
| 207 | ta= | 1 |
| 208 | tra2°p-timi | 1 |
| 209 | trigalloyl-glucoses | 1 |
| 210 | tryptorelin | 1 |
| 211 | tunjuk | 1 |
| 212 | ustekinuman | 1 |
| 213 | vived | 1 |
| 214 | x≥ | 1 |
| 215 | φ~ | 1 |
| 216 | ≥3-within | 1 |
| 1 | +sertraline | 1 |
| 2 | -1.1+/- | 1 |
| 3 | -15±6.4 | 1 |
| 4 | -1h-1,2,4-triazole-3,5-diamine | 1 |
| 5 | -2.9± | 1 |
| 6 | -5-phenyl-1,3,4-oxadiazoles | 1 |
| 7 | -6.00d | 1 |
| 8 | -alpha-2b | 1 |
| 9 | -arylpyrroloindolines | 1 |
| 10 | -but-2-enenitrile | 1 |
| 11 | -n'-benzylidene-5-methyl-1,3-diphenyl-1h-pyrazole-4-carbohydrazide | 1 |
| 12 | -netupitant | 1 |
| 13 | -omeprazole | 1 |
| 14 | -timi | 5 |
| 15 | .adjunctive | 1 |
| 16 | .selenomethionine | 1 |
| 17 | .within | 1 |
| 18 | //www.projetodiretrizes.org.br/4_volume/06-diabetes-c.pdf | 1 |
| 19 | /ethanol | 1 |
| 20 | /mct | 1 |
| 21 | 0.20+/- | 1 |
| 22 | 0.20-1.25 | 1 |
| 23 | 0.20± | 1 |
| 24 | 0.21+/- | 1 |
| 25 | 0.21± | 1 |
| 26 | 0± | 2 |
| 27 | 1-ethynylazulene | 1 |
| 28 | 1.62/dbp | 1 |
| 29 | 1/grade | 1 |
| 30 | 10/hctz | 16 |
| 31 | 11+/- | 1 |
| 32 | 11-minute | 1 |
| 33 | 13/of | 1 |
| 34 | 1500-17 | 1 |
| 35 | 17/ | 3 |
| 36 | 1950-week | 2 |
| 37 | 1969-june | 1 |
| 38 | 1980-week | 4 |
| 39 | 2-aminoadamantane | 1 |
| 40 | 2.37+/-0.27 | 1 |
| 41 | 21of | 2 |
| 42 | 21± | 1 |
| 43 | 22.5± | 1 |
| 44 | 23.3±1.7 | 1 |
| 45 | 23.7°± | 1 |
| 46 | 25-train-of-four | 1 |
| 47 | 25th- | 1 |
| 48 | 27/ | 1 |
| 49 | 27and | 1 |
| 50 | 3-alkynylindoles | 2 |
| 51 | 3-aryl-5,7-dimethoxyquinolin-4-ones | 1 |
| 52 | 3-methylene-2,3-dihydroindoles | 1 |
| 53 | 3-ni | 4 |
| 54 | 3/cplx | 3 |
| 55 | 3/grade | 1 |
| 56 | 305/ | 1 |
| 57 | 333.0±3.6 | 1 |
| 58 | 349.3±3.6 | 1 |
| 59 | 37/ | 1 |
| 60 | 3± | 2 |
| 61 | 4.20mg | 1 |
| 62 | 41- | 1 |
| 63 | 42-minute | 1 |
| 64 | 43+/- | 1 |
| 65 | 43,4± | 1 |
| 66 | 44.7±2.1 | 1 |
| 67 | 5/hctz | 4 |
| 68 | 51.2±0.1.9 | 1 |
| 69 | 54,8 | 1 |
| 70 | 55+/- | 1 |
| 71 | 57.41+/- | 1 |
| 72 | 58+/- | 1 |
| 73 | 5and | 1 |
| 74 | 6/day | 2 |
| 75 | 63.3± | 1 |
| 76 | 7-sample | 1 |
| 77 | 7.0-ph | 1 |
| 78 | 7.9.± | 1 |
| 79 | 72.7+/- | 1 |
| 80 | 78+/- | 1 |
| 81 | 79+/- | 1 |
| 82 | 9-lu | 1 |
| 83 | 9beta,13alpha-dihydroxyisabellione | 1 |
| 84 | adimix | 1 |
| 85 | adolescentes | 1 |
| 86 | airpel | 2 |
| 87 | al-p. | 1 |
| 88 | alendonate | 2 |
| 89 | alfa2a | 1 |
| 90 | alphacalcidiol | 1 |
| 91 | anthracene-1,4-diones | 1 |
| 92 | approixmately | 1 |
| 93 | arrivo | 1 |
| 94 | azd2066 | 10 |
| 95 | b=group | 1 |
| 96 | bp= | 1 |
| 97 | bruker | 8 |
| 98 | c4-spirocyclopropane | 1 |
| 99 | ca2+/creatinine | 1 |
| 100 | capilarema | 1 |
| 101 | ck- | 1 |
| 102 | clarinol™ | 1 |
| 103 | coltolux | 1 |
| 104 | coptis-evodia | 2 |
| 105 | cut-off-level | 1 |
| 106 | cyclohexa-1,3-diene | 1 |
| 107 | death= | 5 |
| 108 | deltaeer-s/r | 1 |
| 109 | dermatoaphagoides | 1 |
| 110 | dimes® | 1 |
| 111 | eat- | 1 |
| 112 | eclia-elecsys | 1 |
| 113 | efforts-has | 1 |
| 114 | elevation≥grade | 2 |
| 115 | enoxaparin/clexane® | 1 |
| 116 | esomeprasol | 1 |
| 117 | esophagitis-weekly | 1 |
| 118 | ex-he | 3 |
| 119 | ex-hn | 119 |
| 120 | ex-lhn | 1 |
| 121 | f3,64 | 3 |
| 122 | follows-after | 1 |
| 123 | fromnt | 1 |
| 124 | fyfanon | 1 |
| 125 | g-laser | 1 |
| 126 | g3- | 1 |
| 127 | gc/v | 1 |
| 128 | ghq-depression | 1 |
| 129 | gog104/swog | 1 |
| 130 | gpc3+hsp70 | 1 |
| 131 | greater-than-or-equal | 2 |
| 132 | ileoileoanastomoses | 1 |
| 133 | imatynib-biofarm | 3 |
| 134 | intake-serum | 1 |
| 135 | interaction≥ | 2 |
| 136 | intratecttm | 1 |
| 137 | intravenous-lps | 1 |
| 138 | jimmy | 2 |
| 139 | kt/vof | 1 |
| 140 | kyse | 2 |
| 141 | level≤ | 1 |
| 142 | levocetrizine | 1 |
| 143 | levorotated | 1 |
| 144 | limax® | 1 |
| 145 | lipovenoes | 4 |
| 146 | lm75/ | 1 |
| 147 | losmapimod/placebo | 1 |
| 148 | m-chlorophenylisocyanate | 1 |
| 149 | macer | 1 |
| 150 | married/at | 1 |
| 151 | md=- | 1 |
| 152 | micomazole | 1 |
| 153 | midasolam | 1 |
| 154 | minusil | 1 |
| 155 | modradoc001 | 3 |
| 156 | modulo | 5 |
| 157 | n-6/n- | 1 |
| 158 | n=continuous | 2 |
| 159 | napdh-oxidase | 1 |
| 160 | neurotrophin- | 1 |
| 161 | niacin/ | 1 |
| 162 | nn= | 1 |
| 163 | nnt= | 1 |
| 164 | novabac | 1 |
| 165 | novopen® | 4 |
| 166 | npz | 1 |
| 167 | o-drive-od | 1 |
| 168 | octaethyloxochlorin | 1 |
| 169 | of≥ | 1 |
| 170 | ondatron | 1 |
| 171 | one-whole | 1 |
| 172 | overload-aim | 1 |
| 173 | oxanthrone | 2 |
| 174 | paltry | 1 |
| 175 | parts-part | 1 |
| 176 | perylene-3,4,9,10-dianhydride | 1 |
| 177 | pg/mol | 1 |
| 178 | phenyl-methyl-siloxane | 1 |
| 179 | physio™ | 1 |
| 180 | placebo→golimumab | 1 |
| 181 | pneumo | 6 |
| 182 | pneumonitis-weekly | 1 |
| 183 | psmin | 2 |
| 184 | q-yag | 1 |
| 185 | quartile-range | 1 |
| 186 | r=0.200 | 1 |
| 187 | reductions-approximately | 1 |
| 188 | repeat-derived | 1 |
| 189 | resvida™ | 1 |
| 190 | rlxu= | 1 |
| 191 | s.d.s | 2 |
| 192 | sarsaponin | 1 |
| 193 | sensitivity= | 1 |
| 194 | seventh-eighth | 1 |
| 195 | sfc/placebo | 1 |
| 196 | sponsor-mandated | 1 |
| 197 | t+nes | 3 |
| 198 | ta= | 1 |
| 199 | tifton | 7 |
| 200 | tra2°p-timi | 1 |
| 201 | trigalloyl-glucoses | 1 |
| 202 | tryptorelin | 1 |
| 203 | tunjuk | 1 |
| 204 | ustekinuman | 1 |
| 205 | vived | 1 |
| 206 | x≥ | 1 |
| 207 | ~ | 180 |
| 208 | φ~ | 1 |
| 209 | ∼ | 260 |
| 210 | ≈ | 258 |
| 211 | ≤day | 4 |
| 212 | ≥ | 8,658 |
| 213 | ≥3-within | 1 |
| 214 | ≧ | 24 |
| 215 | ≳ | 2 |
| 216 | ⩾ | 31 |
| 1 | 0.20+/- | 1 |
| 2 | -1.1+/- | 1 |
| 3 | 11+/- | 1 |
| 4 | 0.21+/- | 1 |
| 5 | 57.41+/- | 1 |
| 6 | 43+/- | 1 |
| 7 | 55+/- | 1 |
| 8 | 72.7+/- | 1 |
| 9 | 58+/- | 1 |
| 10 | 78+/- | 1 |
| 11 | 79+/- | 1 |
| 12 | 41- | 1 |
| 13 | g3- | 1 |
| 14 | md=- | 1 |
| 15 | 25th- | 1 |
| 16 | ck- | 1 |
| 17 | n-6/n- | 1 |
| 18 | neurotrophin- | 1 |
| 19 | eat- | 1 |
| 20 | al-p. | 1 |
| 21 | 305/ | 1 |
| 22 | lm75/ | 1 |
| 23 | 17/ | 3 |
| 24 | 27/ | 1 |
| 25 | 37/ | 1 |
| 26 | niacin/ | 1 |
| 27 | r=0.200 | 1 |
| 28 | gpc3+hsp70 | 1 |
| 29 | 44.7±2.1 | 1 |
| 30 | modradoc001 | 3 |
| 31 | -15±6.4 | 1 |
| 32 | f3,64 | 3 |
| 33 | 0.20-1.25 | 1 |
| 34 | 333.0±3.6 | 1 |
| 35 | 349.3±3.6 | 1 |
| 36 | azd2066 | 10 |
| 37 | 23.3±1.7 | 1 |
| 38 | 1500-17 | 1 |
| 39 | 2.37+/-0.27 | 1 |
| 40 | 54,8 | 1 |
| 41 | 51.2±0.1.9 | 1 |
| 42 | ta= | 1 |
| 43 | death= | 5 |
| 44 | nn= | 1 |
| 45 | bp= | 1 |
| 46 | nnt= | 1 |
| 47 | rlxu= | 1 |
| 48 | sensitivity= | 1 |
| 49 | alfa2a | 1 |
| 50 | coptis-evodia | 2 |
| 51 | capilarema | 1 |
| 52 | -alpha-2b | 1 |
| 53 | placebo→golimumab | 1 |
| 54 | novabac | 1 |
| 55 | -6.00d | 1 |
| 56 | sponsor-mandated | 1 |
| 57 | levorotated | 1 |
| 58 | repeat-derived | 1 |
| 59 | vived | 1 |
| 60 | 5and | 1 |
| 61 | 27and | 1 |
| 62 | o-drive-od | 1 |
| 63 | 1/grade | 1 |
| 64 | 3/grade | 1 |
| 65 | elevation≥grade | 2 |
| 66 | perylene-3,4,9,10-dianhydride | 1 |
| 67 | -n'-benzylidene-5-methyl-1,3-diphenyl-1h-pyrazole-4-carbohydrazide | 1 |
| 68 | quartile-range | 1 |
| 69 | ex-he | 3 |
| 70 | -but-2-enenitrile | 1 |
| 71 | one-whole | 1 |
| 72 | micomazole | 1 |
| 73 | -omeprazole | 1 |
| 74 | 7-sample | 1 |
| 75 | c4-spirocyclopropane | 1 |
| 76 | 2-aminoadamantane | 1 |
| 77 | phenyl-methyl-siloxane | 1 |
| 78 | cyclohexa-1,3-diene | 1 |
| 79 | 1-ethynylazulene | 1 |
| 80 | +sertraline | 1 |
| 81 | -1h-1,2,4-triazole-3,5-diamine | 1 |
| 82 | ca2+/creatinine | 1 |
| 83 | .selenomethionine | 1 |
| 84 | levocetrizine | 1 |
| 85 | 9beta,13alpha-dihydroxyisabellione | 1 |
| 86 | oxanthrone | 2 |
| 87 | 1969-june | 1 |
| 88 | napdh-oxidase | 1 |
| 89 | kyse | 2 |
| 90 | m-chlorophenylisocyanate | 1 |
| 91 | alendonate | 2 |
| 92 | 11-minute | 1 |
| 93 | 42-minute | 1 |
| 94 | .adjunctive | 1 |
| 95 | //www.projetodiretrizes.org.br/4_volume/06-diabetes-c.pdf | 1 |
| 96 | 13/of | 1 |
| 97 | 21of | 2 |
| 98 | kt/vof | 1 |
| 99 | q-yag | 1 |
| 100 | 4.20mg | 1 |
| 101 | gog104/swog | 1 |
| 102 | 7.0-ph | 1 |
| 103 | seventh-eighth | 1 |
| 104 | -timi | 5 |
| 105 | tra2°p-timi | 1 |
| 106 | 3-ni | 4 |
| 107 | 1950-week | 2 |
| 108 | 1980-week | 4 |
| 109 | tunjuk | 1 |
| 110 | greater-than-or-equal | 2 |
| 111 | airpel | 2 |
| 112 | cut-off-level | 1 |
| 113 | minusil | 1 |
| 114 | alphacalcidiol | 1 |
| 115 | pg/mol | 1 |
| 116 | /ethanol | 1 |
| 117 | esomeprasol | 1 |
| 118 | midasolam | 1 |
| 119 | overload-aim | 1 |
| 120 | imatynib-biofarm | 3 |
| 121 | intratecttm | 1 |
| 122 | intake-serum | 1 |
| 123 | ustekinuman | 1 |
| 124 | ex-hn | 119 |
| 125 | ex-lhn | 1 |
| 126 | ≥3-within | 1 |
| 127 | .within | 1 |
| 128 | tryptorelin | 1 |
| 129 | psmin | 2 |
| 130 | sarsaponin | 1 |
| 131 | octaethyloxochlorin | 1 |
| 132 | ghq-depression | 1 |
| 133 | fyfanon | 1 |
| 134 | ondatron | 1 |
| 135 | tifton | 7 |
| 136 | sfc/placebo | 1 |
| 137 | losmapimod/placebo | 1 |
| 138 | modulo | 5 |
| 139 | pneumo | 6 |
| 140 | arrivo | 1 |
| 141 | 1.62/dbp | 1 |
| 142 | b=group | 1 |
| 143 | deltaeer-s/r | 1 |
| 144 | macer | 1 |
| 145 | bruker | 8 |
| 146 | g-laser | 1 |
| 147 | follows-after | 1 |
| 148 | 25-train-of-four | 1 |
| 149 | s.d.s | 2 |
| 150 | efforts-has | 1 |
| 151 | dermatoaphagoides | 1 |
| 152 | 3-alkynylindoles | 2 |
| 153 | 3-methylene-2,3-dihydroindoles | 1 |
| 154 | -5-phenyl-1,3,4-oxadiazoles | 1 |
| 155 | t+nes | 3 |
| 156 | -arylpyrroloindolines | 1 |
| 157 | 3-aryl-5,7-dimethoxyquinolin-4-ones | 1 |
| 158 | anthracene-1,4-diones | 1 |
| 159 | lipovenoes | 4 |
| 160 | trigalloyl-glucoses | 1 |
| 161 | ileoileoanastomoses | 1 |
| 162 | adolescentes | 1 |
| 163 | intravenous-lps | 1 |
| 164 | n=continuous | 2 |
| 165 | eclia-elecsys | 1 |
| 166 | married/at | 1 |
| 167 | /mct | 1 |
| 168 | -netupitant | 1 |
| 169 | fromnt | 1 |
| 170 | parts-part | 1 |
| 171 | 9-lu | 1 |
| 172 | gc/v | 1 |
| 173 | adimix | 1 |
| 174 | 3/cplx | 3 |
| 175 | coltolux | 1 |
| 176 | 6/day | 2 |
| 177 | ≤day | 4 |
| 178 | reductions-approximately | 1 |
| 179 | approixmately | 1 |
| 180 | esophagitis-weekly | 1 |
| 181 | pneumonitis-weekly | 1 |
| 182 | jimmy | 2 |
| 183 | paltry | 1 |
| 184 | npz | 1 |
| 185 | 10/hctz | 16 |
| 186 | 5/hctz | 4 |
| 187 | ~ | 180 |
| 188 | φ~ | 1 |
| 189 | ≈ | 258 |
| 190 | resvida™ | 1 |
| 191 | clarinol™ | 1 |
| 192 | physio™ | 1 |
| 193 | level≤ | 1 |
| 194 | ≥ | 8,658 |
| 195 | of≥ | 1 |
| 196 | interaction≥ | 2 |
| 197 | x≥ | 1 |
| 198 | ≧ | 24 |
| 199 | enoxaparin/clexane® | 1 |
| 200 | novopen® | 4 |
| 201 | dimes® | 1 |
| 202 | limax® | 1 |
| 203 | 7.9.± | 1 |
| 204 | 0± | 2 |
| 205 | 0.20± | 1 |
| 206 | 21± | 1 |
| 207 | 0.21± | 1 |
| 208 | 3± | 2 |
| 209 | 63.3± | 1 |
| 210 | 43,4± | 1 |
| 211 | 22.5± | 1 |
| 212 | -2.9± | 1 |
| 213 | 23.7°± | 1 |
| 214 | ≳ | 2 |
| 215 | ∼ | 260 |
| 216 | ⩾ | 31 |